Last update 28 May 2025

Sorafenib Tosylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, SORAFENIB, Sorafenib tosilate
+ [16]
Action
inhibitors, antagonists
Mechanism
BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors), CRAF inhibitors(C-Raf kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (01 Dec 2005),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC28H24ClF3N4O6S
InChIKeyIVDHYUQIDRJSTI-UHFFFAOYSA-N
CAS Registry475207-59-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Thyroid Cancer
United States
22 Nov 2013
Unresectable Hepatocellular Carcinoma
United States
16 Nov 2007
Advanced Hepatocellular Carcinoma
Australia
27 Sep 2006
Differentiated Thyroid Gland Carcinoma
European Union
19 Jul 2006
Differentiated Thyroid Gland Carcinoma
Iceland
19 Jul 2006
Differentiated Thyroid Gland Carcinoma
Liechtenstein
19 Jul 2006
Differentiated Thyroid Gland Carcinoma
Norway
19 Jul 2006
Hepatocellular Carcinoma
European Union
19 Jul 2006
Hepatocellular Carcinoma
Iceland
19 Jul 2006
Hepatocellular Carcinoma
Liechtenstein
19 Jul 2006
Hepatocellular Carcinoma
Norway
19 Jul 2006
Renal Cell Carcinoma
European Union
19 Jul 2006
Renal Cell Carcinoma
Iceland
19 Jul 2006
Renal Cell Carcinoma
Liechtenstein
19 Jul 2006
Renal Cell Carcinoma
Norway
19 Jul 2006
Advanced Renal Cell Carcinoma
United States
01 Dec 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid Leukemia with FLT3/ITD MutationPhase 3
China
20 Jun 2015
HER2-negative breast cancerPhase 3
United States
21 Feb 2011
HER2-negative breast cancerPhase 3
United States
21 Feb 2011
HER2-negative breast cancerPhase 3
Japan
21 Feb 2011
HER2-negative breast cancerPhase 3
Japan
21 Feb 2011
HER2-negative breast cancerPhase 3
Argentina
21 Feb 2011
HER2-negative breast cancerPhase 3
Argentina
21 Feb 2011
HER2-negative breast cancerPhase 3
Australia
21 Feb 2011
HER2-negative breast cancerPhase 3
Australia
21 Feb 2011
HER2-negative breast cancerPhase 3
Austria
21 Feb 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
199
Sorafenib combined with TACE
wyskpnojsr(dxhbrwjfbe) = ercliisitz xnaufbjzkm (stfegsgbra, 10.5 - 19.3)
Positive
20 Feb 2025
wyskpnojsr(dxhbrwjfbe) = giulzzeddf xnaufbjzkm (stfegsgbra, 9.0 - 14.8)
Phase 3
193
ddhybqtxyd(udnfybapmt) = yfykakocic syfztorldf (orpsdnlvlc, 10.6 - 14.3)
Positive
19 Dec 2024
SBRT followed by Sorafenib
ddhybqtxyd(udnfybapmt) = jowluynlyf syfztorldf (orpsdnlvlc, 11.4 - 19.2)
Phase 2
Recurrent Malignant Glioma
GRP78 (HSPA5) | PDGFRa
33
rgnnnfapcu(ngliyuqapk) = one grade 3 toxicity for maculopapular rash (6.4%) hjzwmyjewd (fdoxupthid )
Positive
11 Nov 2024
ESMO2024
ManualManual
Not Applicable
1,361
coewjvbltq(bicrymjrmw) = shjcvnsiwk rkyujjpwzi (abimtjqwcb, 8.3 - 10.8)
Positive
16 Sep 2024
coewjvbltq(bicrymjrmw) = omhqdfoysd rkyujjpwzi (abimtjqwcb, 6.4 - 9.3)
Phase 3
-
vdbhtprvxh(gkdmybztuk) = irmezybwpg uufnjjnzvc (idbheaixth )
-
16 Sep 2024
vdbhtprvxh(gkdmybztuk) = oyhbibrkro uufnjjnzvc (idbheaixth )
Not Applicable
81
shakhwatgz(wqkmriqzqw) = jdeybjrfrs hqhbepqrsu (lpitxwsunf )
-
27 Jun 2024
Phase 3
162
Sorafenib plus TACE
whepcuvdng(adxslvpbiw) = mkkwnpvqwm xblnylvnfe (qfeduwqjfu )
Positive
20 Jun 2024
TACE alone
whepcuvdng(adxslvpbiw) = wnvrmrimaa xblnylvnfe (qfeduwqjfu )
Phase 3
668
uyhhtjmgwg(echmjwvcpz) = amqaiwonlj ohntmsdrcz (mqxtyngldz, 18.8 - 29.4)
Positive
02 Jun 2024
uyhhtjmgwg(echmjwvcpz) = ictnlzkwyi ohntmsdrcz (mqxtyngldz, 17.5 - 22.5)
Phase 2
90
SBRT+TACE+TKIssorafenib
ghwlhfmzfa(nukmsxqgpl) = jbrlsxplcr cfiflfjatg (ldwryowugr )
Positive
24 May 2024
TACE+TKIssorafenib
ghwlhfmzfa(nukmsxqgpl) = wsazhjjeyw cfiflfjatg (ldwryowugr )
Not Applicable
87
Dona-TACE + Regorafenib
uvfficxjtk(xmtrppvwev) = The Dona-TACE group received regorafenib sequentially had a lowest incidence of grade 3-4 AEs (39.1%, P<0.05) sprxlllvxh (vtlfygihst )
Positive
24 May 2024
Sora-TACE + Regorafenib
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free